demonstrated, in addition to higher weight loss in the group treated with high-dose liraglutide 3.0 mg/day for 32 weeks, significant improvements not only of fasting glucose and HOMA-IR, but also of the post-load glucose measured by OGTT, OGTT-derived insulin sensitivity index (SIOGTT), and corrected the early insulin response to a glucose challenge (IGI/HOMA) compared to placebo [62]
The most common are gastrointestinal (GI) side effects like nausea, diarrhea, and, less commonly, constipation
Participants also experienced improvements in fasting blood glucose, triglyceride, and cholesterol levels
Requests to access these datasets should be directed to Ethics statement The studies involving humans were approved by Institutional Review Board of Chi Mei Hospital (IRB No
For optimal results, use 3+3 Cream